Rockland’s antibody development capabilities include their proven ability to generate critical antibody reagents for the preclinical detection and characterization of specific ASO under consideration as drug candidates. Such antibodies exhibit sequence or modification-specific binding properties depending on the intended use and are suitable for standard applications, including ELISA and immunohistochemistry (IHC).
Read how Rockland has successfully worked with diverse nucleic acid chemical structures for antibody development and helped clients to understand the biochemical properties of target nucleic acids to subsequently design appropriate antibody generation strategies.
Read Article